摘要
目的:研究阿加曲班对急性脑梗死患者的有效性和安全性。方法:选取2019年12月~2021年12月期间某院收治的84例急性脑梗死患者作为研究对象,根据不同治疗方案分为对照组(n=41例)与研究组(n=43例)。对照组行脑梗死常规治疗,研究组在常规治疗基础上加用阿加曲班,两组均持续治疗1个月。比较两组患者神经功能[美国国立卫生研究院卒中量表(NIHSS)]、临床疗效、内皮功能指标[一氧化氮(NO)、内皮素-1(ET-1)、降钙素基因相关肽(CGRP)]水平及不良反应发生情况。结果:治疗后,两组NIHSS评分均降低(P<0.05),且研究组低于对照组(P<0.05)。研究组治疗总有效率(95.35%)高于对照组(75.61%,P<0.05)。两组血清NO、CGRP水平均升高(P<0.05),且研究组高于对照组(P<0.05);两组血清ET-1水平均降低(P<0.05),且研究组低于对照组(P<0.05)。两组均未出现明显的严重出血等不良反应。结论:在脑梗死常规治疗的基础上联合阿加曲班可有效抑制脑梗死患者病情,改善其神经功能缺损程度,缓解内皮功能损伤,且安全性高。
Objective:To study the efficacy and safety of argatroban in acute cerebral infarction.Methods:A total of 84 patients with acute cerebral infarction treated in a hospital from December 2019 to December 2021 were divided into control group(n=41) and study group(n=43) according to different treatment regimens.The control group was treated with conventional therapy for cerebral infarction,whereas the study group was treated with argatroban in addition to the conventional therapy,and both groups were treated for 1 month.The neurological function [National Institutes of Health Stroke Scale(NIHSS)],clinical response,endothelial function parameters [nitric oxide(NO),endothelin-1(ET-1),calcitonin gene-related peptide(CGRP)] and adverse reactions were compared between the two groups.Results:After treatment,the NIHSS score decreased in both groups(P<0.05),and was lower in the study group than that in the control group(P<0.05).The total response rate in the study group(95.35%) was higher than that in the control group(75.61%,P<0.05).The levels of serum NO and CGRP increased in both groups(P<0.05),and were higher in the study group as compared with the control group(P<0.05).The level of serum ET-1 decreased in both groups(P<0.05),and was lower in the study group as compared with the control group(P<0.05).There were no obvious adverse reactions such as serious bleeding in either group.Conclusion:Argatroban combined with the conventional treatment for cerebral infarction can effectively inhibit the cerebral infarction,improve the degree of neurological deficit,relieve endothelial dysfunction,with high safety profile.
作者
于广周
杨扬
董书理
王浩
YU Guang-zhou;YANG Yang;DONG Shu-li;WANG Hao(Department of Neurology,Zhumadian Central Hospital,Zhumadian 463000,China)
出处
《中国合理用药探索》
CAS
2023年第10期79-83,共5页
Chinese Journal of Rational Drug Use
基金
国家重点研发计划(2019YFC1710303)。
关键词
急性脑梗死
阿加曲班
神经功能
有效性
安全性
acute cerebral infarction
argatroban
neurological function
efficacy
safety
